The recent discovery of selective antagonists for the A 2A adenosine receptors has been of great help to further research in this field. One compound, SCH 58261, 5-amino-7-(Ξ²-phenylethyl)-2-(8furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine, is playing a key part in a variety of studies. This r
In vitro pharmacology of SCH 58261, a new potent and selective A2a adenosine receptor antagonist
β Scribed by C. Zocchi; E. Ongini; A. Conti; S. Ferrara; A. Negretti; S. Dionisotti
- Book ID
- 119180096
- Publisher
- Elsevier Science
- Year
- 1995
- Tongue
- English
- Weight
- 159 KB
- Volume
- 31
- Category
- Article
- ISSN
- 1043-6618
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
The tritium labeled form of 5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo[4,3-e] 1,2,4-triazolo[l,5-c]pyrimidine (3H-SCH 58261) was obtained by reduction of 5-amino-7-[2-(2',4',5'-tribromo)phenylethyl]-2-(2-furyl)-pyrazolo[4,3-e] 1,2,4-triazolo[ 1,5clpyrimidine with tritium gas in the presence of 10
The therapeutic application of selective adenosine agonists i s hampered by the difficulty of separating desirable actions from side effects. A non-selective agent, combining A, and A , properties, might have advantages in this regard. In the present study, the pharmacological properties of N-ethyl-